A 58-year-old woman underwent mastectomy for multicentric DCIS. Final pathology shows high-grade DCIS with comedonecrosis, margins negative by 3 mm, no invasion identified in 40 tissue blocks examined. Sentinel lymph node biopsy shows isolated tumor cells (0.1 mm cluster) positive for cytokeratin. The medical oncologist requests input on systemic therapy. Evaluate the significance of the nodal finding and recommendations.
Q2
A 36-year-old woman with BRCA2 mutation and strong family history of breast and ovarian cancer desires risk-reducing surgery. She has 2 young children and plans to have one more child in 2 years. She asks about timing of risk-reducing mastectomy and oophorectomy. Her mother died of ovarian cancer at age 45, and sister diagnosed with breast cancer at age 38. Evaluate the optimal counseling regarding surgical timing.
Q3
A 42-year-old premenopausal woman with newly diagnosed 2.5 cm triple-negative breast cancer and 3 positive axillary lymph nodes completed neoadjuvant chemotherapy. Post-treatment MRI shows residual 1 cm mass in breast and 1 abnormal lymph node. She desires breast conservation. The tumor board must evaluate the surgical plan considering residual disease burden and emerging data on post-neoadjuvant therapy.
Q4
A 70-year-old woman with multiple comorbidities (COPD, CHF, DM) presents with a 3 cm palpable breast mass. Core biopsy shows invasive ductal carcinoma, ER-positive (95%), PR-positive (90%), HER2-negative, grade 1, Ki-67 5%. Staging shows no metastases. Her surgical risk is assessed as high (ASA class 4). Analyze the optimal treatment approach.
Q5
A 48-year-old woman presents with bloody nipple discharge from a single duct in her left breast. No palpable mass is identified. Mammogram is normal. Ductography shows an intraductal filling defect 3 cm from the nipple. MRI shows a 6 mm enhancing lesion in the same location. Analyze the most appropriate next step.
Q6
A 55-year-old woman underwent lumpectomy for a 1.5 cm invasive ductal carcinoma. Final pathology shows negative margins (closest margin 2 mm), grade 2, ER-positive, PR-positive, HER2-negative, and Ki-67 of 18%. Sentinel lymph node biopsy reveals micrometastases (0.5 mm) in 1 of 3 nodes. Analyze the need for additional axillary surgery.
Q7
A 29-year-old lactating woman presents with a 4-day history of right breast pain, erythema, and fever. She has a fluctuant 5 cm mass in the upper outer quadrant. Ultrasound confirms a 4.5 cm abscess. She wants to continue breastfeeding. Apply the appropriate management.
Q8
A 62-year-old woman with inflammatory breast cancer completed neoadjuvant chemotherapy. Physical exam shows decreased erythema and edema, but skin changes persist. PET-CT shows complete metabolic response in the breast and axilla. The tumor board discusses surgical options. Apply the appropriate surgical approach.
Q9
A 38-year-old woman with BRCA1 mutation presents for risk-reducing bilateral mastectomy. During preoperative counseling, she asks about reconstruction options. She is a smoker (1 pack per day for 15 years), BMI 32, and works as a yoga instructor wanting to return to full activity. Apply the most appropriate reconstruction recommendation.
Q10
A 45-year-old woman presents with a 2 cm palpable mass in the upper outer quadrant of her right breast. Mammography shows a spiculated lesion with microcalcifications. Core needle biopsy reveals invasive ductal carcinoma, ER-positive, PR-positive, HER2-negative. Sentinel lymph node biopsy shows no metastases. Apply the appropriate surgical management.
Breast Surgery US Medical PG Practice Questions and MCQs
Question 1: A 58-year-old woman underwent mastectomy for multicentric DCIS. Final pathology shows high-grade DCIS with comedonecrosis, margins negative by 3 mm, no invasion identified in 40 tissue blocks examined. Sentinel lymph node biopsy shows isolated tumor cells (0.1 mm cluster) positive for cytokeratin. The medical oncologist requests input on systemic therapy. Evaluate the significance of the nodal finding and recommendations.
A. Upstage to invasive cancer, recommend chemotherapy and endocrine therapy
B. Perform completion axillary dissection to assess additional nodal involvement
C. Consider isolated tumor cells clinically insignificant, node-negative staging, endocrine therapy only if ER-positive (Correct Answer)
D. Recommend axillary radiation and systemic chemotherapy
E. Repeat pathology review to identify occult invasion
Explanation: ***Consider isolated tumor cells clinically insignificant, node-negative staging, endocrine therapy only if ER-positive***
- Per AJCC guidelines, **isolated tumor cells (ITCs)** (clusters ≤ 0.2 mm or < 200 cells) are staged as **pN0(i+)**, which is considered node-negative disease.
- In the setting of pure **DCIS**, ITCs do not warrant staging as invasive cancer nor do they justify **systemic chemotherapy**; management depends solely on the tumor's **ER-status** for endocrine therapy.
*Upstage to invasive cancer, recommend chemotherapy and endocrine therapy*
- Staging cannot be upgraded to invasive cancer unless a **pathological focus of invasion** is identified in the breast tissue (T category).
- **Chemotherapy** is never indicated for pure DCIS, regardless of high-grade features or the presence of ITCs in the lymph nodes.
*Perform completion axillary dissection to assess additional nodal involvement*
- **Completion axillary lymph node dissection (ALND)** is not indicated for ITCs, as they do not carry the same prognostic weight as macro-metastases.
- In pure DCIS, the presence of ITCs is often attributed to **mechanical transport** of cells during biopsy rather than true metastatic potential.
*Recommend axillary radiation and systemic chemotherapy*
- **Axillary radiation** is reserved for patients with significant nodal burden and is inappropriate for **pN0(i+)** status.
- Because DCIS is a non-invasive, **pre-cancerous lesion** contained within the basement membrane, systemic chemotherapy provides no benefit and unnecessary toxicity.
*Repeat pathology review to identify occult invasion*
- While high-grade DCIS increases the risk of occult invasion, the examination of **40 tissue blocks** is considered exhaustive and standard for ruling out invasion.
- Persistent searching for micro-invasion after comprehensive sampling is unlikely to change the clinical management dictated by the **pN0(i+)** finding.
Question 2: A 36-year-old woman with BRCA2 mutation and strong family history of breast and ovarian cancer desires risk-reducing surgery. She has 2 young children and plans to have one more child in 2 years. She asks about timing of risk-reducing mastectomy and oophorectomy. Her mother died of ovarian cancer at age 45, and sister diagnosed with breast cancer at age 38. Evaluate the optimal counseling regarding surgical timing.
A. Perform both risk-reducing mastectomy and oophorectomy immediately
B. Defer both surgeries until after childbearing is complete
C. Risk-reducing mastectomy now, oophorectomy after completion of childbearing
D. Risk-reducing oophorectomy now, mastectomy after completion of childbearing (Correct Answer)
E. Annual screening only until age 40, then reconsider surgery
Explanation: ***Risk-reducing oophorectomy now, mastectomy after completion of childbearing***
- **BRCA2** carriers are recommended to undergo **risk-reducing salpingo-oophorectomy (RRSO)** by age 40-45 as ovarian cancer has a high mortality rate and lacks effective **screening methods**.
- High-risk breast screening with **MRI** and **mammography** can safely defer **bilateral mastectomy** until the patient completes childbearing and breastfeeding, balancing life-saving prevention with reproductive goals.
*Perform both risk-reducing mastectomy and oophorectomy immediately*
- Performing an **immediate oophorectomy** would cause surgical menopause and permanent **infertility**, preventing the patient's plan to have one more child in 2 years.
- While medically aggressive, this approach disregards the patient's **reproductive autonomy** and psychosocial needs without providing a curative benefit that outweighs the loss of fertility at this stage.
*Defer both surgeries until after childbearing is complete*
- Deferring all surgery increases the window of risk for **ovarian cancer**, which is difficult to detect early and has a significantly poor prognosis compared to breast cancer.
- This approach ignores the strong **family history** (mother died at 45) which suggests a high risk for early-onset malignancy in this specific pedigree.
*Risk-reducing mastectomy now, oophorectomy after completion of childbearing*
- Undergoing **bilateral mastectomy** now would prevent the patient from **breastfeeding** her future child, which may be a significant personal goal.
- Prioritizing mastectomy over oophorectomy is often less critical because **breast surveillance** (MRI/Mammogram) is more reliable than current **ovarian cancer screening** (CA-125/Ultrasound).
*Annual screening only until age 40, then reconsider surgery*
- Relying solely on **screening** is risky for **BRCA2** patients, especially for ovarian cancer where screening has not been proven to reduce mortality or detect early-stage disease reliably.
- Given the family history of a death at age 45, waiting until age 40 to even consider surgery may delay intervention past the point of **clinical benefit** for cancer prevention.
Question 3: A 42-year-old premenopausal woman with newly diagnosed 2.5 cm triple-negative breast cancer and 3 positive axillary lymph nodes completed neoadjuvant chemotherapy. Post-treatment MRI shows residual 1 cm mass in breast and 1 abnormal lymph node. She desires breast conservation. The tumor board must evaluate the surgical plan considering residual disease burden and emerging data on post-neoadjuvant therapy.
A. Mastectomy with reconstruction, no additional systemic therapy
B. Additional neoadjuvant chemotherapy until complete response
C. Lumpectomy, sentinel node biopsy only, regional nodal radiation
D. Lumpectomy, completion axillary dissection, standard adjuvant radiation
E. Lumpectomy, axillary dissection, and consider pembrolizumab based on residual disease (Correct Answer)
Explanation: ***Lumpectomy, axillary dissection, and consider pembrolizumab based on residual disease***
- In high-risk **triple-negative breast cancer (TNBC)** with residual disease after neoadjuvant chemotherapy, the **KEYNOTE-522** trial supports continuing adjuvant **pembrolizumab** to improve event-free survival.
- Since the patient remains **node-positive** after neoadjuvant therapy, a **completion axillary lymph node dissection (ALND)** is indicated rather than sentinel node biopsy alone.
*Mastectomy with reconstruction, no additional systemic therapy*
- **Breast conservation** (lumpectomy) is an appropriate option if negative margins can be achieved, and the patient specifically desires it.
- Patients with **residual disease** after neoadjuvant therapy for TNBC require further systemic treatment, such as **capecitabine** or pembrolizumab, to reduce recurrence risk.
*Additional neoadjuvant chemotherapy until complete response*
- Chemotherapy is not typically continued indefinitely until a **pathologic complete response (pCR)** is achieved; surgical resection is the necessary next step once the standard regimen is completed.
- Delaying surgery for additional rounds of the same chemotherapy in a patient with **residual disease** may allow for further tumor progression or increase toxicity.
*Lumpectomy, sentinel node biopsy only, regional nodal radiation*
- **Sentinel node biopsy** alone is insufficient here because the patient has persistent, biopsy-proven or radiologically **abnormal lymph nodes** after neoadjuvant chemotherapy.
- Current standards for patients who remain **node-positive** after chemotherapy typically require a formal **axillary lymph node dissection** to control regional disease.
*Lumpectomy, completion axillary dissection, standard adjuvant radiation*
- While this address the surgical components, it fails to include the critical **adjuvant systemic therapy** required for residual TNBC.
- Omitting post-neoadjuvant systemic treatment ignores data from the **CREATE-X** or **KEYNOTE-522** trials which show survival benefits for patients with residual TNBC.
Question 4: A 70-year-old woman with multiple comorbidities (COPD, CHF, DM) presents with a 3 cm palpable breast mass. Core biopsy shows invasive ductal carcinoma, ER-positive (95%), PR-positive (90%), HER2-negative, grade 1, Ki-67 5%. Staging shows no metastases. Her surgical risk is assessed as high (ASA class 4). Analyze the optimal treatment approach.
A. Primary endocrine therapy with aromatase inhibitor alone (Correct Answer)
B. Neoadjuvant chemotherapy followed by surgery
C. Lumpectomy under local anesthesia with sedation
D. Modified radical mastectomy under general anesthesia
E. Observation with serial imaging
Explanation: ***Primary endocrine therapy with aromatase inhibitor alone***
- For elderly patients with **multiple comorbidities** and **high surgical risk (ASA class 4)**, the risks of invasive surgery may outweigh the benefits of local control.
- The tumor's biology (**highly ER/PR positive**, **low Ki-67**, and **low grade**) indicates it is extremely responsive to **endocrine therapy**, making it a viable primary treatment to manage disease progression without surgery.
*Neoadjuvant chemotherapy followed by surgery*
- **Chemotherapy** is generally poorly tolerated in patients with **COPD, CHF, and DM**, and is not indicated for low-grade, highly hormone-responsive HER2-negative tumors.
- This approach still necessitates **surgery**, which has been determined to be high risk for this patient.
*Lumpectomy under local anesthesia with sedation*
- While less invasive than general anesthesia, even **minor surgery** and sedation carry significant risks for an **ASA 4** patient with unstable medical conditions.
- **Surgical margins** and follow-up radiation (usually required after lumpectomy) would impose additional burdens that may not improve survival in this clinical context.
*Modified radical mastectomy under general anesthesia*
- **General anesthesia** carries an unacceptably high risk of perioperative mortality and complications in a patient with **severe COPD and CHF**.
- **Modified radical mastectomy** is unnecessarily aggressive for a 3 cm, low-grade tumor that can be managed with less morbid systemic options.
*Observation with serial imaging*
- **Observation alone** allows for uncontrolled local growth of the **invasive ductal carcinoma**, which could eventually lead to skin ulceration or pain.
- Unlike simple observation, **primary endocrine therapy** actively treats the cancer and provides **disease control** with minimal toxicity compared to surgical intervention.
Question 5: A 48-year-old woman presents with bloody nipple discharge from a single duct in her left breast. No palpable mass is identified. Mammogram is normal. Ductography shows an intraductal filling defect 3 cm from the nipple. MRI shows a 6 mm enhancing lesion in the same location. Analyze the most appropriate next step.
A. Observation with repeat imaging in 6 months
B. Core needle biopsy of the lesion
C. Ductoscopy with biopsy
D. Microdochectomy (terminal duct excision) (Correct Answer)
E. Total mastectomy
Explanation: ***Microdochectomy (terminal duct excision)***
- **Spontaneous, unilateral, bloody nipple discharge** from a single duct with a confirmed **intraductal filling defect** is highly suspicious for an **intraductal papilloma** or localized malignancy.
- Surgical excision via **microdochectomy** is both diagnostic and therapeutic, as it removes the entire causative duct system and provides tissue for histopathology to rule out **DCIS** or **papillary carcinoma**.
*Observation with repeat imaging in 6 months*
- **Pathologic nipple discharge** (bloody and spontaneous) cannot be managed by observation alone due to the risk of underlying **malignancy**.
- Delaying surgical evaluation of an **enhancing lesion** on MRI risks allowing a localized cancer to progress.
*Core needle biopsy of the lesion*
- **Core needle biopsy** of a small (6 mm) intraductal lesion is technically difficult, and negative results are often associated with high **sampling error**.
- Even if biopsy shows a benign **papilloma**, complete excision is usually recommended because these lesions can harbor **atypia** or focal carcinoma.
*Ductoscopy with biopsy*
- **Ductoscopy** allows direct visualization but is not widely available and often yields insufficient tissue for a definitive histological grade.
- In the presence of a localized lesion already identified by **ductography** and **MRI**, proceeding directly to surgical excision is the standard of care.
*Total mastectomy*
- This is an overly invasive procedure for a localized **6 mm lesion** in the absence of a confirmed diffuse malignancy or biopsy-proven multicentric disease.
- **Breast-conserving** approaches like microdochectomy are the primary choice for investigating isolated pathologic nipple discharge.
Question 6: A 55-year-old woman underwent lumpectomy for a 1.5 cm invasive ductal carcinoma. Final pathology shows negative margins (closest margin 2 mm), grade 2, ER-positive, PR-positive, HER2-negative, and Ki-67 of 18%. Sentinel lymph node biopsy reveals micrometastases (0.5 mm) in 1 of 3 nodes. Analyze the need for additional axillary surgery.
A. Repeat sentinel lymph node biopsy
B. Axillary radiation instead of surgery
C. Completion axillary lymph node dissection is mandatory
D. No additional axillary surgery needed if receiving whole breast radiation (Correct Answer)
E. Axillary lymph node dissection only if >3 sentinel nodes positive
Explanation: ***No additional axillary surgery needed if receiving whole breast radiation***
- According to the **ACOSOG Z0011** and **IBCSG 23-01** trials, patients with T1-T2 tumors and **micrometastases** (≤2 mm) in sentinel nodes do not benefit from completion dissection if undergoing breast-conserving therapy.
- The use of **whole breast radiation** and systemic therapy provides sufficient regional control for low-volume nodal disease, reducing the risk of **lymphedema**.
*Repeat sentinel lymph node biopsy*
- This procedure is not indicated once a **positive sentinel node** or **micrometastasis** has already been identified and the stage is established.
- **Repeat biopsy** would provide no additional therapeutic or prognostic value over the initial successful SLNB results.
*Axillary radiation instead of surgery*
- While the **AMAROS trial** showed that axillary radiotherapy is an alternative to surgery for positive nodes, it is generally reserved for **macrometastases** rather than small micrometastases.
- In this case, **standard tangential fields** used during whole breast radiation are usually sufficient to cover the level I/II axilla without dedicated axillary-field radiation.
*Completion axillary lymph node dissection is mandatory*
- Completion ALND is no longer considered mandatory for **micrometastases** in patients undergoing breast-conserving surgery and radiotherapy.
- Mandatory dissection in this scenario would cause unnecessary morbidity, such as **nerve injury** and chronic swelling, without improving **overall survival**.
*Axillary lymph node dissection only if >3 sentinel nodes positive*
- Current guidelines (Z0011) suggest that completion ALND can be avoided if there are **1 to 2 positive** sentinel nodes; having 3 or more nodes positive would typically trigger a dissection.
- This option is incorrect because the patient only has **one node** with a micrometastasis, which falls well within the safety criteria for omitting further surgery.
Question 7: A 29-year-old lactating woman presents with a 4-day history of right breast pain, erythema, and fever. She has a fluctuant 5 cm mass in the upper outer quadrant. Ultrasound confirms a 4.5 cm abscess. She wants to continue breastfeeding. Apply the appropriate management.
A. Oral antibiotics and continue breastfeeding from both breasts
B. Incision and drainage with cessation of breastfeeding
C. IV antibiotics alone and pump and discard milk
D. Excisional biopsy of the abscess cavity
E. Ultrasound-guided aspiration, antibiotics, and continue breastfeeding (Correct Answer)
Explanation: ***Ultrasound-guided aspiration, antibiotics, and continue breastfeeding***
- **Ultrasound-guided aspiration** is preferred for abscesses <5 cm as it is less invasive than surgical drainage and has a better cosmetic outcome.
- Continued **breastfeeding or pumping** is essential to prevent milk stasis, which can worsen the infection, and is safe for the infant as long as the nipple is not involved.
*Oral antibiotics and continue breastfeeding from both breasts*
- While antibiotics and breastfeeding are correct components, they are insufficient alone for a **fluctuant 4.5 cm abscess**.
- Active **drainage** (either by needle or incision) is mandatory to resolve a collection of this size and prevent further tissue destruction.
*Incision and drainage with cessation of breastfeeding*
- **Incision and drainage** is generally reserved for very large (>5 cm) or multiloculated abscesses where aspiration has failed.
- **Cessation of breastfeeding** is not recommended as it increases the risk of further milk stasis and the development of a mammary fistula.
*IV antibiotics alone and pump and discard milk*
- Antibiotics cannot penetrate an **abscess cavity** effectively due to the lack of vascularity, making drainage the definitive treatment.
- **Pumping and discarding** milk is unnecessary; the milk from the affected breast is not harmful to the healthy term infant if the mother is on appropriate therapy.
*Excisional biopsy of the abscess cavity*
- An **excisional biopsy** is inappropriate in the setting of acute infection and can lead to poor wound healing and chronic fistulae.
- Biopsies are typically reserved for persistent masses after the infection has resolved to rule out **inflammatory breast cancer**.
Question 8: A 62-year-old woman with inflammatory breast cancer completed neoadjuvant chemotherapy. Physical exam shows decreased erythema and edema, but skin changes persist. PET-CT shows complete metabolic response in the breast and axilla. The tumor board discusses surgical options. Apply the appropriate surgical approach.
A. Breast-conserving therapy with radiation
B. Modified radical mastectomy with reconstruction
C. Modified radical mastectomy without reconstruction (Correct Answer)
D. Simple mastectomy with sentinel node biopsy
E. Continue chemotherapy and defer surgery
Explanation: ***Modified radical mastectomy without reconstruction***
- **Inflammatory breast cancer (IBC)** is an aggressive disease that requires a **modified radical mastectomy** and **axillary lymph node dissection** even if a complete metabolic response is seen on imaging.
- **Immediate reconstruction** is avoided because almost all IBC patients require **post-mastectomy radiation therapy (PMRT)**, which increases the risk of flap or implant complications.
*Breast-conserving therapy with radiation*
- IBC involves diffuse infiltration of the **dermal lymphatics**, making **breast-conserving therapy** contraindicated due to the exceptionally high risk of local recurrence.
- Even with a **complete clinical response**, surgical margins cannot be reliably cleared with a partial mastectomy in IBC patients.
*Modified radical mastectomy with reconstruction*
- While a mastectomy is required, **immediate reconstruction** can interfere with the timely delivery of **adjuvant radiation therapy**, which is a critical component of treatment.
- **Tissue expansion** or flaps may be compromised by high-dose **PMRT**, so reconstruction is typically delayed until oncologic treatment is finished.
*Simple mastectomy with sentinel node biopsy*
- **Sentinel lymph node biopsy (SLNB)** is generally not recommended in IBC because the **dermal lymphatic blockage** by tumor cells can alter lymphatic drainage, leading to high false-negative rates.
- A **simple mastectomy** is insufficient as IBC requires a formal **level I/II axillary lymph node dissection** regardless of the response to chemotherapy.
*Continue chemotherapy and defer surgery*
- Surgery is a mandatory component of the **trimodality therapy** (chemotherapy, surgery, and radiation) required to manage IBC effectively.
- Deferring surgery after **neoadjuvant chemotherapy** in a patient who has achieved a metabolic response increases the risk of local recurrence and disease progression.
Question 9: A 38-year-old woman with BRCA1 mutation presents for risk-reducing bilateral mastectomy. During preoperative counseling, she asks about reconstruction options. She is a smoker (1 pack per day for 15 years), BMI 32, and works as a yoga instructor wanting to return to full activity. Apply the most appropriate reconstruction recommendation.
A. Immediate tissue expander followed by implant placement
B. Immediate autologous TRAM flap reconstruction
C. Delayed reconstruction after smoking cessation (Correct Answer)
D. Immediate DIEP flap reconstruction
E. Implant-based reconstruction with acellular dermal matrix
Explanation: ***Delayed reconstruction after smoking cessation***
- Active **smoking** (1 pack per day) and a high **BMI (32)** significantly increase the risk of **skin flap necrosis**, wound dehiscence, and infection in any reconstructive procedure.
- **Smoking cessation** for at least 4 to 6 weeks is mandatory before breast reconstruction to improve microvascular perfusion and reduce the high risk of surgical complications.
*Immediate tissue expander followed by implant placement*
- **Active smoking** is a major risk factor for **implant loss** and mastectomy flap necrosis, making immediate prosthetic placement hazardous.
- Patients with **BMI >30** have higher rates of prosthetic reconstruction failure and seroma compared to autologous options.
*Immediate autologous TRAM flap reconstruction*
- The **Pedicled TRAM flap** involves sacrificing the rectus muscle, which causes **abdominal wall weakness** and would hinder the patient's career as a **yoga instructor**.
- Smoking is a strong relative contraindication for TRAM flaps due to the high risk of **partial or total flap loss** and fat necrosis.
*Immediate DIEP flap reconstruction*
- While the **DIEP flap** preserves muscle and is ideal for an active lifestyle, the patient's **current smoking status** makes immediate free tissue transfer extremely risky.
- Microsurgical complications and **vascular compromise** are significantly higher in active smokers, necessitating delay until the patient has quit.
*Implant-based reconstruction with acellular dermal matrix*
- Using **Acellular Dermal Matrix (ADM)** in an active smoker increases the risk of **red breast syndrome**, infection, and reconstructive failure.
- Despite providing good support, it cannot mitigate the underlying **ischaemic risks** associated with nicotine use during the acute healing phase.
Question 10: A 45-year-old woman presents with a 2 cm palpable mass in the upper outer quadrant of her right breast. Mammography shows a spiculated lesion with microcalcifications. Core needle biopsy reveals invasive ductal carcinoma, ER-positive, PR-positive, HER2-negative. Sentinel lymph node biopsy shows no metastases. Apply the appropriate surgical management.
A. Lumpectomy with radiation therapy (Correct Answer)
B. Lumpectomy alone without radiation
C. Bilateral mastectomy with reconstruction
D. Simple mastectomy without reconstruction
E. Modified radical mastectomy with immediate reconstruction
Explanation: ***Lumpectomy with radiation therapy***
- **Breast-conserving therapy (BCT)**, which includes lumpectomy followed by **whole-breast radiation**, is the standard of care for early-stage (T1-T2) breast cancer as it offers equivalent **survival rates** to mastectomy.
- In this patient with a **2 cm (T1) tumor** and **negative sentinel lymph nodes (N0)**, local excision with radiation provides excellent local control while preserving the breast.
*Lumpectomy alone without radiation*
- Omitting radiation after lumpectomy is generally only considered in patients **over 70 years old** with small, ER-positive, node-negative tumors (CALGB 9343 trial).
- At age 45, the risk of **local recurrence** is significantly high without adjuvant **radiotherapy**, making this an inappropriate choice for a younger patient.
*Bilateral mastectomy with reconstruction*
- **Bilateral mastectomy** is an invasive over-treatment for unilateral, localized disease unless the patient has a high-risk **genetic mutation** (like BRCA1/2) or strong family history.
- There is no clinical evidence provided that suggests a contralateral risk or patient preference that would justify such an **extensive surgical intervention**.
*Simple mastectomy without reconstruction*
- A **simple mastectomy** (removal of the entire breast tissue) is oncologically equivalent but more disfiguring than BCT for a patient with a localized, small mass.
- This option is typically reserved for patients who have **contraindications to radiation** (e.g., prior chest irradiation or connective tissue disease) or who prefer it to avoid radiotherapy.
*Modified radical mastectomy with immediate reconstruction*
- **Modified radical mastectomy (MRM)** involves removing the breast and **axillary lymph nodes (Levels I-II)**, which is unnecessary here given the **negative sentinel lymph node biopsy**.
- Since the patient is eligible for **breast preservation**, pursuing MRM would lead to unnecessary morbidity and potential complications like **lymphedema**.
